Colorectal News and Research

RSS

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy that would improve median overall survival over IFL (bolus 5-fluorouracil, generics/leucovorin, generics/irinotecan*) plus bevacizumab (Roche/Genentech/Chugai's Avastin), would earn a 60 percent patient share in stage IV colorectal cancer, according to surveyed U.S. oncologists. In Europe, such an agent would earn a 50 percent patient share, according to surveyed European oncologists.

16 Mar 2010

Gene defects could become targets for new personalised treatments for bowel cancer

Cancer Research UK-funded scientists have discovered that the gene defects that cause some bowel cancers could become the targets for new personalised treatments. Their research is published in Cancer Cell today (Monday).

16 Mar 2010

Impact of tumor surgery on sexual function

Sexual problems are frequent after operations for carcinoma of the rectum. Christian Schmidt et al. describe the consequences for quality of life in the current issue of Deutsches -rzteblatt International (Dtsch Arztebl Int 2010; 107[8]: 123-30).

15 Mar 2010

Latest treatment options for colorectal cancer highlighted at NCCN Annual Conference

Despite statistics stating that colorectal cancer is the fourth most frequently diagnosed cancer in men and women in the United States, mortality from colon cancer has decreased slightly over the past 30 years, possibly because of earlier diagnoses through screening and better treatment modalities.

15 Mar 2010

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for full year and fourth quarter, ended December 31, 2009. These results are included in the Company’s Annual Report on Form 10-K which has been filed with the SEC.

12 Mar 2010

Vermont: Only state to pass bill mandating coverage of colon cancer screening

Progress towards nationwide, state-mandated coverage of colon cancer screening according to accepted medical guidelines has slowed to a crawl as state legislators await the outcome of the health care reform debate at the federal level, a coalition of public health associations and medical professional societies reported today. With a better grade for only a single state – Vermont – 2009 marks the least improvement in a single year since the Colorectal Cancer Legislation Report Card began in 2004.

12 Mar 2010

InvestorSoup.com announces investment report featuring Exact Sciences

InvestorSoup.com announces an investment report featuring Exact Sciences Corp. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

11 Mar 2010

Eureka Genomics announces closing of $3.7M private financing round

Eureka Genomics today announced the closing of a $3.7 million private financing round whose participants included private individuals and undisclosed angel investors. The proceeds will further discovery research aimed at identifying novel microorganisms associated with specific cancers and other important diseases, as well as help grow Eureka Genomics’ high-throughput sequencing and bioinformatics service business on a global basis.

11 Mar 2010

CPRIT grants $6.8 million for cancer prevention programs

The Cancer Prevention and Research Institute of Texas today awarded over $6.8 million to fund twelve new cancer prevention programs through local clinics, health districts, community-based organizations, and academic institutions across the state of Texas.

10 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

Campaign to Stop Colon Cancer Now launched in conjunction with National Colorectal Cancer Awareness Month

The Campaign to Stop Colon Cancer Now, a campaign to increase screenings and prevent the nation's second-leading cancer killer, launched today in conjunction with National Colorectal Cancer Awareness Month in March.

10 Mar 2010

IBS patients are at no greater risk of having polyps, colon cancer than healthy people undergoing colonoscopies

Patients with irritable bowel syndrome are at no greater risk of having polyps, colon cancer or inflammatory bowel diseases than healthy people undergoing colonoscopies, according to new research published in the American Journal of Gastroenterology.

10 Mar 2010

Nanoparticles: Targeted cancer therapy

Another weapon in the arsenal against cancer: Nanoparticles that identify, target and kill specific cancer cells while leaving healthy cells alone.

9 Mar 2010

Viatronix V3D-Colon software used for the President's colon cancer screening exam

Viatronix Incorporated, a Stony Brook, New York, based company announced that its V3D-Colon software is used at the National Naval Medical Center where the President's annual physical was done. "Our software is being utilized at several DOD facilities since the landmark Virtual Colonoscopy clinical trial published in the New England Journal of Medicine back in December 2003," said Zaffar Hayat, President of Viatronix Incorporated.

9 Mar 2010

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.

8 Mar 2010

Screening rates among racial and ethnic minorities vary compared to non-Hispanic community: Study

Boston University School of Medicine's researchers have found that sociodemographic characteristics are related to a patients' willingness to participate in cancer screenings. They found this was more important than both attitudinal barriers and medical facilitors. This study appears in the March issue of the Journal of the National Medical Association.

6 Mar 2010

Increased risk of colorectal cancer associated with obesity may be restricted to tumors that have no MSI

The increased risk of colorectal cancer associated with obesity may be largely restricted to tumors that have no or low microsatellite instability (MSI), a common condition in most colorectal cancers, according to a new study published online March 8 in the Journal of the National Cancer Institute.

6 Mar 2010

Study reports increased incidence of colorectal cancer in China

The incidence of colorectal cancer (CRC) in China is lower than that in the west countries, but has increased in recent years and become a substantial cancer burden in China, particularly in the more developed areas.

6 Mar 2010

Study explores prognostic biomarkers in patients with lymph node-negative colorectal cancer

Tumor budding at the invasive tumor front of colorectal cancer is recognized as an independent prognostic factor significantly related to both lymph node and distant metastasis.

5 Mar 2010

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

Saladax Biomedical, Inc. announced today the close of an $8.4 million Series C Preferred offering led by Excel Venture Management of Boston. Participants included Golden Seeds LLC, Ben Franklin Technology Partners, and the Life Sciences Greenhouse of Central Pennsylvania, as well as a number of angel investors. The funding will be used to accelerate product development and expand clinical support of Saladax’s MYCARE™ line of diagnostic tests, which measure blood levels of cancer and Central Nervous System (CNS) disorder drugs, providing physicians with guidance to personalize patient dosing for optimal efficacy.

5 Mar 2010

Colorectal News and Research

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Gene defects could become targets for new personalised treatments for bowel cancer

Impact of tumor surgery on sexual function

Latest treatment options for colorectal cancer highlighted at NCCN Annual Conference

Pro-Pharmaceuticals reports net loss applicable to common stock of $1.3M for fourth-quarter 2009

Vermont: Only state to pass bill mandating coverage of colon cancer screening

InvestorSoup.com announces investment report featuring Exact Sciences

Eureka Genomics announces closing of $3.7M private financing round

CPRIT grants $6.8 million for cancer prevention programs

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Campaign to Stop Colon Cancer Now launched in conjunction with National Colorectal Cancer Awareness Month

IBS patients are at no greater risk of having polyps, colon cancer than healthy people undergoing colonoscopies

Nanoparticles: Targeted cancer therapy

Viatronix V3D-Colon software used for the President's colon cancer screening exam

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Screening rates among racial and ethnic minorities vary compared to non-Hispanic community: Study

Increased risk of colorectal cancer associated with obesity may be restricted to tumors that have no MSI

Study reports increased incidence of colorectal cancer in China

Study explores prognostic biomarkers in patients with lymph node-negative colorectal cancer

Saladax Biomedical announces closing of $8.4M Series C Preferred offering

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News